Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

MTNB vs VTGN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

VTGN Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 3–3 Matrix Metrics)

VTGN Overall Winner 6-Pillar Tally: MTNB 0 – 4 VTGN (2 Tie) Matrix Metrics: MTNB 3 – 3 VTGN

As of Nov 19, 2026, Vistagen Therapeutics, Inc. (VTGN) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas VTGN carries 42.3/100 (HOLD) at $0.19 (N/M Forward P/E, -2543.1% operating margin).

  • Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. VTGN 42.3/100 HOLD), VTGN captures the overall institutional head-to-head verdict (3–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-2543.1% vs. 0.0% operating margin) and revenue trajectory (-46.5% vs. -100.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MTNB vs VTGN
MTNB NYSE American
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.81
-10.98% 1D
Market Cap $979,904
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -7.20β · 147% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 33.0 · SMA20: $1.26 · SMA50: $1.47
VTGN NASDAQ Head-to-Head Winner
Vistagen Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$0.19
-6.47% 1D
Market Cap $9.0M
TTM Revenue $2.4M
Forward P/E N/M
Beta / 30D Vol 1.23β · 80% Vol
Unified Composite Score
42.3 / 100 HOLD
Tech 20.0 Fund 52.0 Flow 69.0 Mom 54.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.0 · SMA20: $0.18 · SMA50: $0.22

6-Pillar Scorecard Institutional Category Breakdown (MTNB 0 – 4 VTGN)

Columns: Metric · MTNB · VTGN
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale VTGN
Revenue Growth (YoY) -100.0% -46.5%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A $2.4M
Market Cap $979,904 $9.0M
3. Profitability & Quality VTGN
Gross Margin N/A 100.0%
Operating Margin 0.0% -2543.1%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -147.5% -144.9%
4. Balance Sheet & Cash Flow VTGN
Cash Generation (TTM) N/A -$60M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.2M Net Cash $30M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning VTGN
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) 274.8% (71st %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MTNB (3) vs VTGN (3)
Institutional Metric MTNB VTGN Criterion Row Edge
Market Capitalization
Scale
$979,904 $9.0M Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-100.0% -46.5% Higher Growth VTGN
Operating Margin (TTM)
Profitability
0.0% -2543.1% Higher Margin MTNB
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-147.5% -144.9% Higher ROE VTGN
52-Week Range Position
Momentum
22% ($0–$3) 0% ($0–$5) Stronger Trend MTNB
Beta / 30D Volatility
Risk Regime
-7.20β · 147% Vol 1.23β · 80% Vol Lower Realized Risk VTGN
Unified Institutional Score
Composite Signal
54.6 / 100 (HOLD) 42.3 / 100 (HOLD) Higher Composite MTNB
Trailing 12M Revenue (USD)
Operating Scale
N/A $2.4M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.2M Net Cash) -$60M EBITDA ($30M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon VTGN +43.08 pp
MTNB: -46.7% · VTGN: -3.62%
3M Horizon MTNB +331.01 pp
MTNB: +307.49% · VTGN: -23.52%
6M Horizon MTNB +91.64 pp
MTNB: +20.93% · VTGN: -70.71%
1Y Horizon MTNB +64.62 pp
MTNB: -31.35% · VTGN: -95.97%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MTNB Revenue VTGN Revenue MTNB Op. Margin VTGN Op. Margin Margin Leader
FY2019 $0M N/A -21067.4% N/A MTNB
FY2020 $0M N/A -15288.4% N/A MTNB
FY2021 $0M $0M -74954.5% -1646.1% VTGN
FY2022 $0M $0M -771.3% -4308.3% MTNB
FY2023 $0M N/A -2168.4% N/A MTNB
FY2024 N/A $0M N/A -3103.5% VTGN
FY2025 N/A $0M N/A -11517.1% VTGN
FY2026 N/A $0M N/A -5683.7% VTGN

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MTNB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
VTGN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 274.8%
IV Percentile 71st %ile
Put/Call OI Skew N/A
IV Regime Elevated (60th–80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact VTGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MTNB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
VTGN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $9.0M market capitalization and -2543.1% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MTNB vs VTGN Key Questions & Quantitative Answers

As of Nov 19, 2026, Vistagen Therapeutics, Inc. (VTGN) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 3–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas VTGN carries 42.3/100 (HOLD) at $0.19 (N/M Forward P/E, -2543.1% operating margin). Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. VTGN 42.3/100 HOLD), VTGN captures the overall institutional head-to-head verdict (3–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (-2543.1% vs. 0.0% operating margin) and revenue trajectory (-46.5% vs. -100.0% YoY).

VTGN leads the Growth & Scale pillar: MTNB posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with VTGN at -46.5% YoY revenue growth and +0.0% YoY earnings growth on $2.4M TTM revenue (100.0% gross margin, -2543.1% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), MTNB cumulative revenue shifted N/A while VTGN shifted N/A. In operating R&D and SG&A reinvestment, MTNB deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for VTGN.

MTNB and VTGN trade at balanced relative valuation multiples. MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas VTGN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTNB (-147.5% ROE) versus VTGN (-144.9% ROE) capital efficiency.

In options market volatility and institutional positioning, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk). By comparison, VTGN carries 274.8% implied volatility (71st %ile, Elevated (60th–80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 80% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.